{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-044597","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.806961+00:00","generated_at":"2026-06-07T14:13:43.951757+00:00","sec_items":["1.01","1.02","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aditxt to acquire Evofem for ~$100M in stock and debt assumption; expected close H1 2024","bullets":["Evofem shareholders to receive 610,000 shares of Aditxt common stock; preferred stock to note, warrant, and preferred holders.","Aditxt assumes ~$18M in senior secured notes; to pay $5M by year-end 2023, $8M by Sep 2024, plus up to $5M more.","Termination fee of $4M if Evofem accepts a superior proposal; both boards unanimously approved the deal.","Evofem posted $13.4M net sales of Phexxi in first 9 months of 2023; non-hormonal birth control market valued at $27.7B in 2022.","Closing conditions include shareholder approvals, SEC registration effectiveness, and Aditxt regaining Nasdaq compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-044597","json":"https://secwatch.observer/filing/0001493152-23-044597.json","markdown":"https://secwatch.observer/filing/0001493152-23-044597.md","text":"https://secwatch.observer/filing/0001493152-23-044597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223044597/0001493152-23-044597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223044597/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:13:43.951757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40777f9ae8e84e8a8849282c791c781c36dfd893","claim":"Evofem Biosciences, Inc.: Filed a Certificate of Designations creating Series F-1 Preferred Stock, specifying rights, preferences, and privileges (effective 2023-12-11).","evidence_excerpt":"On December 11, 2023 the Company filed a Certificate of Designations creating a new series of preferred stock designated as \"Series F-1 Preferred Stock.\"","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223044597/0001493152-23-044597-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-12-11"}],"fact_type":"governance_change"},{"claim_id":"ba3257705d2d967d992df2f21029101d063d5781","claim":"Evofem Biosciences, Inc. entered into Merger Agreement with Aditxt, Inc. and Adicure, Inc. (effective 2023-12-11).","evidence_excerpt":"On December 11, 2023, Evofem Biosciences, Inc. (“Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Aditxt, Inc., a Delaware corporation (“Parent”), Adicure, Inc., a Delaware corporation and a wholly-owned Subsidiary of parent (“Merger Sub”), pursuant to which, and on the terms and subject to the conditions thereof, Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the “Merger”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223044597/0001493152-23-044597-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Aditxt, Inc. and Adicure, Inc."},{"label":"Effective","value":"2023-12-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}